Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma. [electronic resource]
Producer: 20210601Description: 800-811 p. digitalISSN:- 1573-0646
- Adenocarcinoma -- drug therapy
- Aged
- Albumins -- therapeutic use
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Carcinoma, Pancreatic Ductal -- drug therapy
- Chemokine CCL2 -- antagonists & inhibitors
- Cohort Studies
- Deoxycytidine -- analogs & derivatives
- Female
- Humans
- Male
- Middle Aged
- Paclitaxel -- therapeutic use
- Pancreatic Neoplasms -- drug therapy
- Prognosis
- Pyrrolidines -- therapeutic use
- Small Molecule Libraries -- therapeutic use
- Tumor Microenvironment -- drug effects
- Gemcitabine
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.